131I-Metuximab (brand name Licartin) is a radiolabeled murine antibody developed at the Fourth Military Medical University and brought on the market by the company Chengdu Huasun Technology Group The drug is targeting CD147 and was launched in China in 2006. The drug is only available in China.

Target/Mechanism: CD147

Leading Emitter: beta electrons (β)